| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| Other Sizes |
|
Purity: ≥98%
| References |
Roston TM, Dewar L, Franciosi S, Hathaway J, Bartels K, Cunningham T, Gibbs KA, Sheps S, Laksman ZWM, Sanatani S, Krahn AD. The accessibility and utilization of genetic testing for inherited heart rhythm disorders: a Canadian cross-sectional survey study. J Community Genet. 2017 Nov 23. doi: 10.1007/s12687-017-0348-y. [Epub ahead of print] PubMed PMID: 29170972.
|
|---|
| Molecular Formula |
C9H7N2O5
|
|---|---|
| Molecular Weight |
223.164
|
| Exact Mass |
222.028
|
| CAS # |
4693-01-0
|
| Related CAS # |
4693-01-0
|
| PubChem CID |
78414
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.551g/cm3
|
| Boiling Point |
392.4ºC at 760mmHg
|
| Flash Point |
191.1ºC
|
| Index of Refraction |
1.623
|
| LogP |
0.923
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
16
|
| Complexity |
350
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(N(C)C1=CC=C([N+]([O-])=O)C=C12)OC2=O
|
| InChi Key |
FJSZPPSFHYCQHQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H6N2O5/c1-10-5-3-2-4-6(11(14)15)7(5)8(12)16-9(10)13/h2-4H,1H3
|
| Chemical Name |
1-methyl-5-nitro-2H-benzo[d][1,3]oxazine-2,4(1H)-dione
|
| Synonyms |
1M 7 1M-7 1M7
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~450.15 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.25 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (11.25 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4811 mL | 22.4054 mL | 44.8109 mL | |
| 5 mM | 0.8962 mL | 4.4811 mL | 8.9622 mL | |
| 10 mM | 0.4481 mL | 2.2405 mL | 4.4811 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05462145 | RECRUITING | Device: Globe Pulsed Field System | Paroxysmal Atrial Fibrillation Persistent Atrial Fibrillation |
Kardium Inc. | 2023-03-09 | Not Applicable |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA